NEW YORK (GenomeWeb) – Analyzing results from more than 20,000 clinical samples, researchers at Natera and their collaborators have found that noninvasive prenatal screening for DiGeorge syndrome, also known as 22q11.2 deletion syndrome, classified almost 0.5 percent of cases as high risk, among them at least 11 true cases but also at least 50 false positives.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.